Research Paper Volume 16, Issue 9 pp 8155—8170

Bioinformatics analysis and validation of mesenchymal stem cells related gene MT1G in osteosarcoma

Sikuan Zheng1,2,3, *, , Xifu Cheng4, *, , Sulun Ke5, , Linyi Zhang4, , Hui Wu1,2,3, , Dingwen He1,3, , Xigao Cheng1,3, ,

  • 1 The Second Affiliated Hospital of Nanchang University, Nanchang, China
  • 2 The Second Clinical College, Medical College of Nanchang University, Nanchang, China
  • 3 Institute of Orthopedics of Jiangxi Province, Nanchang, China
  • 4 School of Ophthalmology and Optometry, Nanchang University, Nanchang, China
  • 5 Nanchang University Queen Mary School, Jiangxi Medical College of Nanchang University, Nanchang University, Nanchang, China
* Equal contribution

Received: October 5, 2023       Accepted: March 18, 2024       Published: May 13, 2024      

https://doi.org/10.18632/aging.205809
How to Cite

Copyright: © 2024 Zheng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Osteosarcoma (OS) is a primary malignant bone tumor arising from mesenchymal cells. The standard clinical treatment for OS involves extensive tumor resection combined with neoadjuvant chemotherapy or radiotherapy. OS's invasiveness, lung metastasis, and drug resistance contribute to a low cure rate and poor prognosis with this treatment. Metallothionein 1G (MT1G), observed in various cancers, may serve as a potential therapeutic target for OS.

Methods: OS samples in GSE33382 and TARGET datasets were selected as the test cohorts. As the external validation cohort, 13 OS tissues and 13 adjacent cancerous tissues from The Second Affiliated Hospital of Nanchang University were collected. Patients with OS were divided into high and low MT1G mRNA-expression groups; differentially expressed genes (DEGs) were identified as MT1G-related genes. The biological function of MT1G was annotated using Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO) and gene set enrichment analysis (GSEA). Gene expression correlation analysis and competing endogenous RNA (ceRNA) regulatory network construction were used to determine potential biological regulatory relationships of DEGs. Survival analysis assessed the prognostic value of MT1G.

Results: MT1G expression increased in OS samples and presented higher in metastatic OS compared with non-metastatic OS. Functional analyses indicated that MT1G was mainly associated with spliceosome. A ceRNA network with DEGs was constructed. MT1G is an effective biomarker predicting survival and correlated with increased recurrence rates and poorer survival.

Conclusions: This research identified MT1G as a potential biomarker for OS prognosis, highlighting its potential as a therapy target.

Abbreviations

OS: Osteosarcoma; MT1G: Metallothionein 1G; DEGs: differentially expressed genes; KEGG: Kyoto Encyclopedia of Genes and Genomes; GO: Gene Ontology; GSEA: gene set enrichment analysis; CeRNA: competing endogenous RNA; MSCs: Mesenchymal stem cells; BMSCs: Bone marrow MSCs; GEO: Gene Expression Omnibus; PCA: principal component analysis; PCs: principal components; IHC: immunohistochemistry; PPI: protein-protein interaction; MCODE: Molecular Complex Detection; DELs: long noncoding RNAs; MiRNAs: microRNAs; KM: Kaplan-Meier; ROC: receiver operating characteristic; PCA: The principal component analysis; MTs: Metallothioneins.